cdk7 in 7

CDK7-IN-7, a highly potent and selective inhibitor of CDK7 kinase, exhibits remarkable activity with an IC50 of less than 50 nM.

CDK7 9-IN-1 is a specific inhibitor of cyclin-dependent kinases 7 9 (CDK7 9). It specifically targets CDK7, while also displaying inhibitory activity against CDK9. CDK7 9-IN-1 demonstrates excellent inhibitory potency against CDK7, with IC50 values of 0.0656 μM and 0.00574 μM without pre-incubation and after 3 hours pre-incubation, respectively. Furthermore, CDK7 9-IN-1 inhibits CDK9 with an IC50 of 2.14 μM after 3 hours pre-incubation. Its application in cancer research makes it valuable for such investigations.

CDK7 9 tide is peptide substrate for CDK7 or CDK9[1]. [1]. Robert T, et, al. Development of a CDK10 CycM in vitro Kinase Screening Assay and Identification of First Small-Molecule Inhibitors. Front Chem. 2020 Feb 27; 8:147.

CDK7 12-IN-1 是一种 CDK7 12 的选择性抑制剂，作用于 CDK7 (IC50: 3 nM) 和 CDK 12 (IC50: 277 nM)。抑制 CDK7 和 CDK12 是一种有效抑制肿瘤生长的有效。

CDK7 ligand 2 (Compound A6) 作为一种CDK7配体，主要用于PROTACs的合成。

CDK7-IN-31（compound 13）是一款高效的口服活性细胞周期蛋白依赖性激酶 7（cyclin-dependent kinase 7 (CDK7)）抑制剂，Kd 值达到了 0.18 nM。此化合物具备明显的抗癌效果。

CDK7-IN-5, a CDK7 inhibitor with an IC 50 value of less than 100 nM, exhibits potent anticancer properties (WO2015154022A1, Compound 104).

CDK7-IN-1 is an analog derived from YKL-5-124 and functions as an inhibitor of cyclin-dependent kinase 7 (cdk7). It exhibits strong inhibitory activity, with an IC50 value of less than 100 nM (WO 2016105528 A2, Compound 215).

CDK7-IN-2 hydrochloride hydrate (Example 6) is a highly effective and specific inhibitor of the CDK7 enzyme. This compound exhibits significant anti-cancer properties.

CDK7-IN-6 is a highly effective and specific inhibitor (IC50 ≤100 nM) of cyclin-dependent kinase 7 (CDK7). It showcases remarkable selectivity, with more than a 200-fold preference for CDK7 over CDK1, CDK2, and CDK5. This compound holds significant potential for cancer research purposes.

CDK7-IN-16 (compound 9) 是一种 CDK 7 的有效抑制剂 (IC50: 1-10 nM)。CDK7-IN-16 能够用于研究抗癌，特别是转录异常的癌症。

CDK7-IN-20 是一种有效的、选择性的、不可逆的 CDK7(CDK) 抑制剂，IC50值为 4 nM。CDK7-IN-20 对 CDK7的选择性超过 CDK1、CDK2、CDK3、CDK5、CDK6、CDK9 和 CDK12的 206 倍以上。CDK7-IN-20 具有用于常染色体显性多囊肾病 (ADPKD) 研究的潜力。

CDK7-IN-25 (CY-16-1)为一CDK-7抑制剂，具有极低的半抑制浓度(IC50<1nM)，主要用于癌症研究领域。

HDAC1 CDK7-IN-1（compound 8e）是一款针对CDK7和HDAC1的双重抑制剂，其IC50值分别为893 nM 和248 nM 。该化合物能有效抑制MDA-MB-231、MCF-7、A549及HCT-116等多种癌细胞系的生长。此外，HDAC1 CDK7-IN-1在HCT-116细胞中诱发了细胞周期阻滞与凋亡（apoptosis）现象，并能够抑制其细胞迁移能力。